Innovation Acta News

2018

  • DEC
    21
    PROJECT APPROVED IN THE 2017 IMI2 JU - CALL 12

    NECESSITY


    necessity

    European Commission notification of funding

    NEClinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients”

    The project aim to develop of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS).

    Project Coordinator: Prof. Xavier Mariette (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM)
    Project Leader: Dr. Peter Gergely (NOVARTIS PHARMA AG - Novartis)

    Starting Date: 1 January 2019
    End Date: 31 December 2024

    Total Budget: € 15.485.964,84


    List of Beneficiaries

  • DEC
    10

    INTEGRATA Kick-off Meeting


    integrata

    integrata

    The INTEGRATA Kick-off Meeting was held at Hotel Cenobio dei Dogi in Camogli (Genoa), Italy on 10th December 2018 and was organised by the coordinating Institution, UNIGE with the support of INN-ACTA.

    INTEGRATA is a MSCA-funded project aimed at providing a group of early stage researchers (ESRs) with a highly interdisciplinary and intersectoral training in drug discovery, focusing specifically on NAD production and on NAD/nucleotide signaling as targets for the development of new cancer therapeutics. INTEGRATA will train 14 ESRs in an overarching training programme involving training-by-research, joint courses of technical, scientific and transferrable skills, participation to public scientific events, and an intense intersectoral networking exchange plan (secondments). The INTEGRATA consortium encompasses academic institutions, research centers, and SMEs, all with proven experience in higher education and training, and state-of-the art scientific and technical expertise and infrastructures. Six countries are represented: Italy, Germany, the United Kingdom, Switzerland, Spain and France.

    More on project website

  • OCT
    10-12

    Meet in Italy for Life Sciences 2018, 5th edition


    meet in italy

    Innovation Acta will take part in the conference Meet in Italy for Life Sciences 2018, 5th edition in Bologna (Italy)
    Please contact us, If you would like to have a face to face meeting.

  • SEP
    18

    RESTORE submitted proposal for stage 2


    restore

    restore

    The consortium "RESTORE Health by Advanced Therapies" submitted the proposal for the preparatory action phase on September 18, 2018. RESTORE is supported by >250 stakeholders from science, industry, non-profit organizations and patient representatives throughout Europe and beyond (USA, Asia), underlining the importance of Advanced Therapies for the scientific and public society.

    More on project website

  • AUG
    4
    PROJECT APPROVED IN THE H2020-SC1-2018-Single-Stage-RTD CALL

    RESHAPE


    reshape

    European Commission notification of funding

    Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches - from Advanced Technology Developments to First-in-Human Trials”

    The project aims to transform the treatment of patients suffering from undesired Immunity/inflammation (Allotransplantation, Autoimmunity, Hyperinflammation, and Regenerative Medicine, including gene therapy) who presently have limited curative treatment options by applying next-generation Treg approaches that overcome the limitations of 1st generation Treg product developments.

    Project Coordinator: Charité Universitätsmedizin Berlin

    Starting Date: 1 January 2019
    End Date: 31 December 2022

    Total Budget: € 13.137.396,25

    More on project website

  • JUL
    30

    RESTORE F2F Meeting


    restore

    restore

    The Steering Board of the Large scale Research Initiative RESTORE met at the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) in Berlin. The Board discussed further how to unlock the potential of Advanced Therapies in Europe and defined comprehensive work packages for the next phase of the European Commission’s (EC) Large scale Research Initiative competition.

    More on project website

  • MAY
    30
    PROJECT APPROVED IN THE H2020-MSCA-ITN-2018 CALL

    INTEGRATA


    integrata

    European Commission notification of funding

    “Integrating chemical and biological approaches to target NAD production and signaling in cancer”

    INTEGRATA is a European Training Network (ETN) funded in the framework of H2020 Marie Skłodowska-Curie ITN programme. The INTEGRATA network aims at the education of promising young scientists who will learn the key steps of the modern discovery process of new drugs and therapeutic approaches in general (i.e. enzyme inhibition measurements, toxicities on cell cultures, preliminary pharmacological parameters, and in vivo proof-of-concept studies), with a main focus on NAD-producing enzymes and enzymes mediating NAD and nucleotide signaling in cancer treatment.

    Project Coordinator: Prof. Alessio Nencioni Dept. Internal Medicine and Medical Specialties (DIMI), University of Genoa, Italy

    Starting Date: 1 November 2018
    End Date: 31 October 2022

    More on project website

  • MAY
    18

    RESTORE


    restore

    RESTORE project passed the stage 1 and is preparing for stage 2.

    More on project website

  • JAN
    17

    New projects


    inn-acta

    4 ITN Proposals submitted under the Call MSCA-ITN-2018.

   


Innovation Acta S.r.l. | Via D.A. Azuni, 9 - 00196 Roma - Italy | VAT number: 13201341008

© 2020 Innovation Acta - All rights reserved

PRIVACY

Innovation Acta S.r.l.
VAT number: 13201341008

+39 0577 1652729
  +39 366 3746125

  info@innovationacta.eu
  acta_srl@pec.it

Registered office:
Via D.A. Azuni, 9 - 00196 Roma - Italy


Operational headquarters:
Via delle Province, 1 - 53100 Siena - Italy


Operational headquarters:
Campo di Pile c/o Confindustria - 67100 L'Aquila